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A novel signalling screen demonstrates that CALR mutations
activate essential MAPK signalling and facilitate
megakaryocyte differentiation
K Kollmann1,2,7, W Warsch1,2,7, C Gonzalez-Arias1,2, FL Nice1,2, E Avezov3, J Milburn1,2, J Li1,2, D Dimitropoulou1,2, S Biddie1,2, M Wang1,2,
E Poynton1,2, M Colzani4, MR Tijssen4, S Anand1,2, U McDermott5, B Huntly1,2,6 and T Green1,2,6
Most myeloproliferative neoplasm (MPN) patients lacking JAK2 mutations harbour somatic CALR mutations that are thought to
activate cytokine signalling although the mechanism is unclear. To identify kinases important for survival of CALR-mutant cells, we
developed a novel strategy (KISMET) that utilizes the full range of kinase selectivity data available from each inhibitor and thus takes
advantage of off-target noise that limits conventional small-interfering RNA or inhibitor screens. KISMET successfully identiﬁed
known essential kinases in haematopoietic and non-haematopoietic cell lines and identiﬁed the mitogen activated protein kinase
(MAPK) pathway as required for growth of the CALR-mutated MARIMO cells. Expression of mutant CALR in murine or human
haematopoietic cell lines was accompanied by myeloproliferative leukemia protein (MPL)-dependent activation of MAPK signalling,
and MPN patients with CALR mutations showed increased MAPK activity in CD34 cells, platelets and megakaryocytes. Although
CALR mutations resulted in protein instability and proteosomal degradation, mutant CALR was able to enhance megakaryopoiesis
and pro-platelet production from human CD34+ progenitors. These data link aberrant MAPK activation to the MPN phenotype and
identify it as a potential therapeutic target in CALR-mutant positive MPNs.
Leukemia advance online publication, 2 December 2016; doi:10.1038/leu.2016.280
INTRODUCTION
In 2005, a single recurrent gain-of-function mutation in the JAK2
tyrosine kinase (JAK2V617F) was discovered in the majority of
patients with myeloproliferative neoplasms (MPNs),1–4 with this
discovery allowing precise diagnosis and catalysing the develop-
ment of several therapeutic JAK2 inhibitors. In 2013, somatic CALR
mutations were identiﬁed in most JAK2-unmutated patients with
essential thrombocythaemia or primary myeloﬁbrosis patients.5,6
Multiple CALR mutations that generated a +1 bp frameshift
and resulted in mutant proteins with a novel C-terminus were
demonstrated in exon 9. One insertion (K385fs*47) and one
deletion (L367fs*46) mutation were particularly common (together
constituting 85% of CALR mutations), with these separate
mutations exhibiting different disease associations. Several lines
of evidence, such as the consistent generation of a novel
C-terminus and the lack of truncating mutation, indicate that
mutations are gain-of-function (for example, consistent generation
of novel C-terminus; lack of truncating mutations).
CALR is ubiquitously expressed and normally resides in the
endoplasmic reticulum (ER), where it ensures proper glycoprotein
folding and also contributes to calcium storage and modulation of
calcium homoeostasis.7,8 In addition, CALR functions outside the
ER, at the cell surface and in the extracellular matrix, where it is
described to modulate cellular processes, including adhesion,
blood function, gene expression and phagocytosis.9–12 However,
the cellular and biochemical consequences of CALR mutations
remain largely unknown. CALR mutations and JAK2/myeloproli-
ferative leukemia protein (MPL) mutations are almost completely
mutually exclusive in MPN patients, suggesting that mutant CALR
also activates cytokine signalling. In support of this, ectopic
expression of mutant CALR in interleukin-3 (IL3)-dependent
murine Ba/F3 cells conferred (MPL)-dependent increased JAK/
STAT phosphorylation together with cytokine-independent
growth,13 and expression proﬁling of granulocytes from patients
with JAK2-mutant or CALR-mutant MPNs suggested many
similarities.14 However, analysis of direct STAT targets from
primary megakaryocytes revealed substantial differences in STAT
signalling downstream of JAK2 and CALR mutations,15 and CALR-
mutant MARIMO cells lack active JAK–STAT signalling and are
unresponsive to JAK2 inhibitors.16
Many kinases play key roles in multiple pathways downstream
of cytokine signalling. The human genome encodes 518 protein
kinases,17 the dysregulation of which is associated with a wide
range of human diseases.18 A rewiring of cellular signalling
networks underlies the development and evolution of many forms
of cancer, with multiple kinase pathways often corrupted within a
single tumour. Although there are multiple examples of classical
oncogene dependence with a single kinase representing a point
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of vulnerability,19 it is frequently difﬁcult to predict exactly which
kinases most strongly contribute to tumour pathogenesis.
Functional in vitro screens have been widely used to address this
challenge, and include the use of libraries of small-interfering RNA
(siRNA) constructs or small-molecule inhibitors.20,21 However such
screens often generate large numbers of false-positive hits, forcing
researchers to allocate signiﬁcant resources to validation and
follow-up studies of each potential candidate kinase. The most
problematic source of false-positive results are ‘off-target’ effects
and much effort has been spent trying to reduce this
background noise.
Here we report a novel approach that turns off-target noise to
our advantage. KISMET (Kinase Inhibitor Screen for Mapping
Essential Targets) provides a reliable and inexpensive method for
identifying essential kinases, and identiﬁed the mitogen activated
protein kinase (MAPK) pathway as essential for CALR-mutant
MARIMO cells. We demonstrate that mutant CALR, although
unstable and readily degraded in a proteasome-dependent
manner, activates MAPK signalling and triggers enhanced mega-
karyocytic differentiation.
MATERIALS AND METHODS
Cell lines, infections and transient transfections
Marimo, K562, HEL, UKE-1, SET-2, HL-60, Dami, Ba/F3 and 32D cells were
cultured in RPMI (Sigma, St Louis, MO, USA), 10% fetal calf serum (Life
Technologies, Waltham, MA, USA) and penicillin/streptomycin (100 U/ml,
100 mg/ml). UKE-1 cells were cultured in 20% fetal calf serum. HEK293T
(293T) were cultured in Dulbecco's modiﬁed Eagle's medium (Sigma), 10%
fetal calf serum (Life Technologies) and penicillin/streptomycin (100 U/ml,
100 mg/ml). Human wild-type CALR and mutant CALR insertion
(K385fs*47) and deletion (L367fs*46) cDNA, alone or fused to FLAG or
FLAG-mCherry, were cloned into the pCDF1-MSC2-EF2-copGFP lentiviral
vector (System Biosciences, Palo Alto, CA, USA) or the pCCL-PPT-MNDU3-
PGK-GFP lentiviral vector22 and sequence-veriﬁed. In addition, all
constructs carrying a FLAG or FLAG-mcherry had a signal peptide site at
their N-terminus, enabling CALR to enter the endoplasmatic reticulum.
Lentivirus was produced by transient transfection of 293T cells and
concentrated with Lenti-X concentrator (Clontech, Saint-Germain-en-Laye,
France). Cell lines have been infected with concentrated lentivirus
(multiplicity of infection of 20, as titered on HEK293T cells) with 8 μg/ml
polybrene for 12 h prior to washing and were sorted for GFP expression
24 h after infection. Human CD34+ cell-enriched populations from cord
blood (490% pure) were isolated by immunomagnetic selection with the
CD34 Microbead Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Isolated cells were cultured in a density of 1 × 105 cells/ml in SCGM
(CellGenix, Freiburg im Breisgau, Germany) with 100 ng/ml hTPO and
10 ng/ml hIL-1β. After 2 days cells have been exposed to concentrated
lentivirus (multiplicity of infection of 50, as titered on HEK293T cells) with
8 μg/ml polybrene for 12 h prior to washing and were sorted for GFP
expression 24 h after infection. 293T cells have been transiently transfected
with Turbofect (Life Technologies) according to the manufacturer’s
protocol.
Western blots and co-immunoprecipitation
Cell lysates were made and immunoblotting was performed as described
previously.23,24 Antibodies used during the study were CALR (Millipore,
Darmstadt, Germany), HSC-70 and β-actin (Santa Cruz, Dallas, TX, USA),
ERK1/2, pERK1/2, MEK1/2, pMEK1/2 (all Cell Signaling, Danvers, MA, USA)
and FLAG (Abcam, Cambridge, UK). For co-immunoprecipitations 1000 μg
of cell lysates were incubated with Anti-FLAG M2 Magnetic Beads (M8823;
Sigma) and protein has been immunoprecipitated according to the
manufacturer's protocol. Samples were heated for 5 min at 95 °C to
separate beads from proteins. The reaction mixtures were run on a sodium
dodecyl sulphate polyacrylamide gel.
Real-time PCR and and RAS–RAF sequencing
For real-time PCR RNA was isolated using TriZol (Invitrogen, Carlsbad, CA,
USA). First-strand cDNA synthesis and PCR-ampliﬁcation were performed
using the Tetro cDNA FAST qPCR Master Mix (Bioline, London, UK)
according to the manufacturer’s instructions. qPCR was performed using
KAPA SYBR FAST qPCR Master Mix (KAPA Biosystem, Waltham, MA, USA).
The following primer sequences were used: CALR F: GAGCCTGCCG
TCTACTTCA and R: AACTGAGAACGAATTTGCCA. Each experiment was
performed in duplicates and results were normalized by comparison with
RPLPO mRNA expression.
For RAS–RAF sequencing cDNA synthesis was carried out using Tetro
cDNA synthesis kit (Bioline) according to the manufacturer’s instructions.
PCR was carried out using AmpliTaq Gold 360 PCR Master Mix (Thermo
Fisher, Wilmington, MA, USA). Ten cycles of touchdown PCR from 68 to 58 °
C followed by 30 cycles at 58 °C with extension times of 2 min were used
for ampliﬁcation according to the manufacturer's instructions. The primers
used for sequencing are shown in Supplementary Table S3.
Following primers were used to sequence RAF and RAS genes: ARAF1 F:
AAGAGAGGCCCAAGATGGAG, R: CTGAGATTGGCTCCCTGGT; ARAF2 F: ACCT
CAGCCCATCTTGACAA, R: GTCCCGATCCTCTTCAGCAG, BRAF1 F: GGCT
CTCGGTTATAAGATGGC, R: CGGAACAGAAAGTAAAGCCT CT; BRAF2 F: ATAC
CACAGGAAGAGGCGTC, R: GCACATTGGGAGCTGATGAG; CRAF1 F: CCTGGC
TCC CTCAGGTTTAA, R: ACATGTGTTCTGCCTCTGGA; CRAF2 F: GGAGTCCCAG
CACTACCTTC, R: ATCCTGCA TTCGGATCACCT; HRAS F: CTGTGAACGGTGG
GGCAG, R: ACTGTGATCCCATCTGTGCC; KRAS F: ATTTCGG ACTGGGAGCG
AG, R: AGAATCATCATCAGGAAGCCC; N-RAS F: CCGCATGACTCGTGGTTC,
R: AGGGAGTA ACAAGAGGTGCA.
Flow cytometric analysis and intracellular FACS staining
Transient transfected 293T cells were analysed for GFP and mCherry
expression (MFI and %) over time. For megakaryocytic differentiation of
infected CD34+ cord blood cells, CD41 (APC-Cy7 conjugated; Biolegend,
San Diego, CA, USA) and CD42a (APC conjugated; Miltenyi Biotec)-positive
cells were determined after 8 days of hTPO and hIL-1ß treatment. Percent
of GFP-expressing infected cord blood cells have been analysed over time
for cell growth. All experiments have been analysed by a Becton Dickinson
(BD) Fortessa LSR II and data were analysed in Flowjo (FLowJo, LLC,
Ashland, OR, USA). Intracellular FACS staining has been performed as
described before25 using antibodies against pMEK1/2 (PE Mouse anti-MEK1
(pS218)/MEK2 (pS222); BD) and pSTAT5 (Alexa Fluor 647 Mouse Anti-Stat5
(pY694); BD).
Pro-platelet forming assay, platelet isolation, purity measurement
and differentiation of patient CD34+ cells
After 8 days of differentiation, infected cord blood CD34+ cells were
counted and the same number of cells was plated in SCGM (CellGenix) on
ﬁbrinogen-coated (200 mg/ml) 96-well plates. After 4–7days the assay was
analysed. The percentage of pro-platelet-forming megakaryocytes have
been counted against the total number of megakaryocytes adhering to the
surface.26
Platelets from patients and healthy volunteers have been isolated, lysed
in sodium dodecyl sulphate sample buffer and prepared for western blot
as described previously.23,27 Purity of platelets have been measured using
an ABC VET hematology analyser (Scil Animal Care, Gurnee, IL, USA).
Patient progenitor cell-enriched populations from peripheral blood were
sorted for CD34 expression using a CD34 antibody (PE conjugated; BD
Bioscience). Sorted cells were cultured in a density of 1 × 105 cells/ml in
SCGM (CellGenix) with 100 ng/ml hTPO and 10 ng/ml hIL-1β. After 10 days
cells were analysed for CD41 and CD42a expression and immediately lysed
with sodium dodecyl sulphate sample buffer.23
Microscopy
Prior to immunoﬂuorescence staining cells were ﬁxed with 4% parafor-
maldehyde, permeabilized with 0.5% Triton X-100/phosphate-buffered
saline and blocked with 10% goat serum/phosphate-buffered saline. To
visualize the ER chicken anti Bip IgY28 was used as primary and goat anti-
chicken IgG conjugated to Alexa647 (Life Technologies) as secondary
antibodies. FLAG-tagged CALR variants were detected using mouse
monoclonal anti-FLAG as primary (Sigma-Aldrich, St Louis, MO, USA), and
goat anti mouse IgG conjugated to Alexa Fluor488 (Jackson Immuno
Research Laboratories, West Grove, PA, USA) as secondary antibodies.
Nuclei were counterstained with Hoechst 33342 (2μg/ml in phosphate-
buffered saline). The stained samples were analysed by the laser scanning
confocal microscopy system (LSM 780; Carl Zeiss, Jena, Germany) with a
Plan-Apo-chromat × 60 oil immersion lens (NA 1.4).
Materials and methods on the KISMET method (cell lines, kinase
inhibitors, statistics, single-dose–response values, combination of two off-
target data sets, selection of kinases used for KISMET and algorithm for the
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calculation of the kinase rank) can be found in the Supplementary
Information.
RESULTS
Development of a drug on- and off-target based screen to identify
essential kinases
In order to identify signalling pathways essential for cells
harbouring CALR mutations, we developed a novel kinase
inhibitor screen that utilizes kinase selectivity data for each
inhibitor and thus takes advantage of their off-target proﬁles
(KISMET, kinase inhibitor screen for mapping essential targets).
A key aim was to establish an approach that would be of broad
utility for the identiﬁcation of essential kinases required in a
variety of transformed cellular contexts. The kinase selectivity
proﬁle of more than 200 kinase inhibitors for over 85% of the
human kinome has recently been reported (Supplementary Data
Set S1).29,30 Although most kinases lacked a highly speciﬁc
inhibitor, each kinase was inhibited by off-target activities of
several inhibitors (Supplementary Figures S1A and B). To establish
the KISMET assay we included 279 kinases, showing the strongest
afﬁnity for 202 inhibitors (see Materials and methods for details).
To increase speed and reduce cost, it was decided to utilize a
single concentration of each inhibitor. The aim was to use a
dosage that would cause the majority of inhibitors to affect most
cell lines, without killing all cells within 72 h. Preliminary
experiments using an inhibitor concentration range of 1–5 μM
demonstrated that a concentration of 4 μM maximized the
heterogeneity of the response of the cell lines to a panel of 70
inhibitors. Using this concentration of 4 μM for all 202 inhibitors
against a panel of 44 cell lines, the mean cell survival at 72 h was
66% with 152 inhibitors inducing an average cell death of more
than 10% but only four inhibitors causing more than 90%
cell death.
The method is outlined in Figure 1a. Cells of interest were
added to the kinase inhibitors in 96-well plates and the number of
viable cells was assessed after 72 h. An algorithm was developed
to integrate these data (Input 1; Figure 1b) with the kinase
selectivity proﬁles of the 202 inhibitors (Input 2; Figure 1b) and
thus generate a score for each kinase, enabling them to be ranked
according to their importance for survival and/or proliferation of
the test cells (see Materials and methods for details). Results for
each test cell line were related to a panel of comparator cell lines,
thus allowing discrimination between cell-selective targets and
those that are essential for most cell types. Two different
comparator panels were used: one composed of 29 haemato-
poietic cell lines (panel A), which was used when a hematopoietic
cell line was screened, and a second composed of 15 non-
hematopoietic cell lines (panel B), which was used for each
non-hematopoietic test cell line (Supplementary Figure S1C).
A detailed description of KISMET and the algorithm can be found
in the Materials and methods section of the Supplementary
Information. The ﬁnal output of KISMET for a given cell line is a
score for each kinase which allows the kinases to be ranked for
that cell line. The closer a kinase score is to 1.0 the more
‘important’ the kinase is for the test cells.
KISMET reveals a highly active MAPK pathway in CALR-mutant
MARIMO cells
To validate KISMET, we initially focused on six cell lines known to
be dependent on either the JAK2V617F mutation (UKE-1, HEL and
SET-2)31 or the BCR-ABL1 fusion (Ku812, K562 and LAMA84).32 For
HEL and Ku812 the top 10 kinases ranked by their kinase score are
shown in Figure 2a. KISMET ranked JAK2 at position 1, 2 and 2 in
the three JAK2V617F mutant cell lines and ABL1 at position 1 in all
three BCR-ABL1-positive cell lines (Supplementary Figures S2A
and B). The complete kinase ranking of all cell lines is shown in
Supplementary Data Set S2.
To further investigate the accuracy and reliability of KISMET, we
then studied 34 different cancer cell lines reported to be addicted
to a total of 15 distinct kinases (Supplementary Table S1) together
with 10 cell lines with no kinase addiction reported. For each cell
line with a known kinase addiction, the KISMET assay resulted in
the correct addicted kinase being ranked in the top 7 out of 279
kinases in 32 of 36 cases demonstrating that KISMET provides a
sensitive method for identifying essential kinases (Figure 2b and
Supplementary Table S2; Supplementary Data Set S2; HL-60 and
EOL-1 were included twice since they are each addicted to two
distinct kinases). Moreover, the essential kinase was ranked highly
in addicted cell lines but not in most non-addicted lines (Figure 2c
and Supplementary Data Set S2), indicating that KISMET also
displays substantial speciﬁcity. Indeed, most false-positive results
reﬂected the fact that, since many inhibitors cannot distinguish
between closely related kinases, cell lines addicted to one kinase
may give rise to a high kinase rank for related family members or
for kinases with similar drug selectivity proﬁle. As an example of
this JAK3 was ranked highly in JAK2-dependent cell lines, and
EGFR (ERBB1) was ranked highly in ERBB2-dependent cell lines.
Overall the known essential kinase had a kinase score of ⩽ 5.0 in
30 of 36 cell lines with a known kinase addiction (Supplementary
Figure S2C), and in each of the 44 screened cell lines KISMET
identiﬁed ⩽ 6 kinases (mean± s.d. = 3.3 ± 1.3, mode = 4) with a
kinase score ⩽ 5.0. These data indicate that further investigation of
maximally four candidates would sufﬁce to identify the correct
essential kinase in 84% of cases. Having established the utility of
KISMET, it was then used to interrogate the CALR-mutant MARIMO
cell line. Whereas JAK2 was ranked ﬁrst or second in all three
JAK2V617F-positive cell lines, it was ranked at position 215 in
MARIMO cells (Supplementary Data Set S2). By contrast four of the
top seven kinases were members of the RAF/MEK/ERK–MAPK
pathway (MEK2, MEK1, RAF1 and ERK2 at positions 2, 5, 6 and 7,
respectively) (Figure 2d). This pattern was unique to MARIMO cells
and was not observed in 12 other human myeloid cell lines. Dose–
response assays were then performed on MARIMO, HEL and K562
cells using AZD 6244 (an inhibitor of ERK1/2 and MEK1) and
PD0325901 (an inhibitor of MEK1/2) which has not been included
in the KISMET assay. MARIMO cells were extremely sensitive,
demonstrating low IC50 values for both inhibitors compared with
the control cell lines (Figures 2e and f). Consistent with these
results, western blot analysis demonstrated substantial levels of
phosphorylated MEK1/2 and ERK1/2 in MARIMO cells (Figure 2g).
Together these data show that MARIMO cells harbour an active
MAPK pathway which is essential for their growth. To exclude
whether mutations in RAF or RAS genes are responsible for the
observed hyper-activation of the MAPK pathway, we sequenced
the genes A-, B- and C-RAF as well as K-, H- and N-RAS. No changes
were detected except a silent mutation in the gene N-RAS (g.
A54A, p.A11A; Supplementary Figure S2D).
Mutant CALR activates the MAPK pathway and encodes an
unstable protein
MARIMO cells may contain other oncogenic changes and our
MARIMO data do not show that CALR mutations play a causal role
in activating the MAPK pathway. To investigate whether mutant
CALR causes increased MAPK signalling, murine IL3-dependent
32D cells were infected with lentiviral CALR constructs (Figure 3a).
Transcript levels of exogenous WT and mutant CALR were similar
to each other and to endogenous CALR transcript levels in human
haematopoietic cell lines (Figure 3b). In the absence of IL3, both
WT and mutant CALR failed to rescue proliferation, in contrast to
BCR-ABL (Figure 3c), and we did not observe any activation of
ERK1/2 (Supplementary Figure S3A). No altered proliferation was
detected in the presence of IL3 (Supplementary Figure S3B). Using
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Figure 1. Development of KISMET to screen for essential kinases in cancer cell lines. (a) Work ﬂow to generate dose–response data of cancer
cells treated with 202 different kinase inhibitors. Dose–response data and the detailed inhibitor off-target proﬁle are integrated into an
algorithm which outputs a score for each of the 279 kinases, enabling them to be ranked according to their importance for the survival and/or
proliferation of the cells. (b) A simpliﬁed ﬂowchart of the algorithm is shown.
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Figure 2. A screen of cancer cell lines with known kinase addictions proves high reliability and robustness of KISMET. (a) List of top 10 kinases
as ranked by the algorithm for the JAK2-dependent cell line HEL and the BCR-ABL1-dependent cell line Ku812. (b) Thirty-six cell lines with
known kinase addictions (based on inhibitor studies and/or RNAi mediated knock down of the respective kinase) were screened with KISMET.
HL-60 and EOL-1 have been included twice since they have been shown to be addicted to two kinases. The graph shows the rank of the
essential kinase for each cell line, as calculated by the algorithm. (c) Each column is composed of 44 dots, each of which represents the rank of
the kinase indicated below for one of 44 screened cell lines. Orange or red coloured dots represent the kinase ranks of cell lines known to be
addicted to the indicated kinase; white and grey dots depict kinase ranks of cell lines not known to be addicted to the indicated kinase. (d)
The CALR-mutant cell line MARIMO has been screened with KISMET. Shown are the kinase ranks for the MAPK members MEK1, MEK2, ERK1,
ERK2 and RAF1 in MARIMO cells as well as 12 other human myeloid cell lines. (e, f) MARIMO, HEL (JAK2V617F+) and K562 (BCR-ABL1+) cells have
been used to perform 10-point dose–response assays with the MEK1/2 and ERK1/2 inhibitor AZD 6244 (e) or the MEK1/2 inhibitor PD0325901
(f). The tables below show the IC50 values for all three cell lines upon 72 h of treatment. (g) The haematopoietic human cell lines UKE-1 and
SET-2 (both JAK2V617F+ MPN), HL-60 (NRAS Q61L+ AML) as well as MARIMO, HEL and K562 cells have been analysed by western blot for their
MEK1/2 and ERK1/2 activation.
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an antibody that recognized both murine and human CALR, total
CALR protein levels were increased in cells harbouring WT CALR
but not mutant CALR, raising the possibility of altered protein
translation or degradation (Figure 3d). Similar results were
obtained using a second cytokine-dependent murine cell line,
Ba/F3 (Supplementary Figures S3C–E).
Since neither 32D nor Ba/F3 cells express MPL, we assessed the
consequences of expressing exogenous MPL. Ba/F3-MPL cells
harbouring mutant CALR exhibited TPO-independent proliferation
(Figure 3e and Supplementary Figure S3F) and showed increased
levels of pERK1/2 in the absence of TPO (Figure 3f). Furthermore,
intracellular FACS data conﬁrmed that mutant CALR-driven
phosphorylation of MEK1/2 depends on the presence of MPL
(Figure 3g). We further detected an MPL-dependent activation of
STAT5 by mutant CALR, which is consistent with recently
published western blot data13 (Supplementary Figure S3G).
Interestingly, no expression of MPL was observed in MARIMO
cells on the mRNA or protein level (Supplementary Figures S3H–I),
suggesting that mutant CALR uses an alternative pathway or
receptor to activate the MAPK pathway in MARIMO cells.
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To extend our analysis of MAPK signalling to human cells with
megakaryocytic potential initial experiments were performed
using the DAMI cell line.33 To monitor protein levels of exogenous
CALR, constructs with an N-terminal FLAG tag were generated
using a lentiviral vector (Figure 3j). WT and mutant CALR
constructs gave rise to equivalent transcript levels (Figure 3k),
and both insertion and deletion mutants gave rise to clearly
increased levels of pERK1/2 and pMEK1/2 (Figure 3j). Of particular
note, an antibody to FLAG detected WT but not mutant CALR
fusion proteins (Figure 3j). Similar results were obtained using HEL
cells (Supplementary Figures S3H and I), a second cell line that can
also undergo megakaryocytic differentiation.34 Low levels of
mutant CALR could be detected if immunoprecipitation was used
to enrich for the FLAG-CALR fusion proteins (Figure 3k) and also by
using transient transfection to produce high levels of transfected
construct per cell (Figure 3l).
Together these data demonstrate that mutant CALR causes
MAPK activation in both murine and human haematopoietic cells,
that this is MPL-dependent in the absence of TPO and that mutant
CALR constructs generate substantial lower protein levels than
their WT equivalents.
Mutant CALR is rapidly targeted by the proteosomal machinery
We have previously shown that mutant CALR with a C-terminal
FLAG tag showed a normal pattern of ER expression.6 Since
mutant CALR has a novel C-terminal sequence, we considered
the possibility that a C-terminal tag might have masked the
consequences of the CALR mutations and therefore used
constructs with an N-terminal FLAG tag (Figure 3f). Using a FLAG
antibody, tagged WT CALR was readily detected in all transfected
(GFP positive) cells. By contrast, tagged mutant CALR was only
detected in o10% of transfected cells and in those cells it
exhibited an abnormal distribution pattern (Figure 4a). To allow
more sensitive detection of mutant CALR fusion proteins FLAG-
mCherry-CALR fusion constructs were generated and expressed in
293T cells (Figure 4b). Transfection efﬁciency was similar in cells
receiving WT or mutant CALR as indicated by equivalent
expression of GFP (Figure 4c), and, the CALR fusion protein was
detected in most transfected cells infected with WT or mutant
constructs (Figure 4d). However, the level of mCherry-CALR
expression was much lower in cells receiving mutant CALR
constructs compared with those receiving the WT construct
(Figure 4e and Supplementary Figure S4A).
To further explore the low levels of mutant CALR protein,
transiently transfected 293T cells were treated with the protein
synthesis inhibitor cycloheximide (Figure 4f). Levels of WT CALR
were stable whereas mutant CALR levels rapidly declined
indicating that mutant CALR protein is less stable than its WT
counterpart, a ﬁnding that is in line with previously published
data.35 Cells harbouring CALR fusion constructs were then treated
with the proteasome inhibitor MG132 and mCherry-CALR expres-
sion was subsequently analysed by FACS. Levels of WT CALR were
stable over 24 h after MG132 treatment whereas levels of both
insertion and deletion mutants rapidly increased, indicating that
the mutant protein instability relates to an increased proteosomal
degradation (Figure 4g).
Together these data demonstrate that mutant CALR is unstable
and undergoes proteosomal degradation, but is nonetheless
able to activate the MAPK pathway in murine and human
haematopoietic cells.
Mutant CALR enhances megakaryopoiesis and pro-platelet
formation in human cord blood cells
To explore the biological consequences of CALR mutations in
primary cells human CD34+ haematopoietic stem and progenitor
cells were infected with lentiviral constructs expressing WT and
mutant CALR and grown in the presence of TPO and IL1 QUOTE to
favour megakaryocytic differentiation (Figure 5a). Compared with
WT CALR, expression of mutant CALR did not alter the number of
transfected cells and their viability during the differentiation time
course (Supplementary Figures S5A and B) but did give rise to an
increased proportion of CD41+CD42+ cells (Figure 5b). Moreover
cells harbouring mutant CALR also generated increased levels of
pro-platelet formation in four independent experiments (Figure 5c
and Supplementary Figures S5C–E). These data are consistent with
the megakaryocytic phenotype exhibited by CALR-mutant MPN
patients and demonstrate that mutant CALR enhances the
formation of megakaryocytes and platelets.
In view of our results demonstrating that mutant CALR can
activate MAPK signalling in vitro, we next explored whether the
MAPK pathway was activated in primary cells from CALR-mutant
patients using three complementary approaches. Firstly JAK2-
unmutated MPN patients, in whom intracellular signalling proteins
had previously been assessed using phopho-ﬂow,36 were geno-
typed for CALR mutations. Compared with equivalent bone
marrow-derived populations from healthy controls, CD34− cells
Figure 3. Ectopic expression of mutant CALR enhances MAPK signalling. (a) 32D or Ba/F3 cells have been infected with an empty lentivirus
(EV) or a lentivirus encoding for human wild-type CALR (WT) or CALR deletion (L367fs*46) mutation (DEL). Two days later cells have been
sorted for GFP expression and cultured for another 2–5 days before analysis. (b) Real-time PCR of human CALR mRNA levels for 32D empty
vector (EV), wild-type CALR (WT) and deletion mutant CALR (DEL) cells (n= 3 cell lines/construct) and four human myeloid cell lines is shown.
Human CALR mRNA has been normalized to RPLP0 mRNA. Bar graphs depict the fold change in human CALR mRNA compared with 32D
WT cells. (c) Proliferation assay was performed by plating the same cell numbers of 32D EV, WT and DEL cells (n= 3 cell lines/construct)
without IL3. 32D cells infected with a virus encoding for BCR-ABL served as a positive control. Total cell numbers were determined over 5 days.
(d) Western blot depicting total CALR protein levels of 32D EV, WT, INS and DEL cells. (e) Ba/F3-MPL cells expressing WT or CALR mutants were
kept in TPO-free medium and cells were counted for 4 days. (f) Ba/F3-MPL cells were infected with a lentivirus encoding for EV, WT or CALR
mutants. Shown is a western blot for ERK1/2 and pERK1/2 of cells starved for 4 h (left) and upon 30 min of TPO (10 ng/ml) stimulation (right).
(g) Parental Ba/F3 and Ba/F3-MPL cells infected with a lentivirus encoding EV, WT or CALR mutants have been starved for 4 h. An intracellular
FACS analysis for pMEK1/2 has been performed. The bar graphs depict the fold change in pMEK1/2 mean ﬂuorescence intensity (MFI)
compared with EV-control cells. (h) Dami or HEL cells have been infected with an empty lentivirus (EV) or a lentivirus encoding for FLAG-CALR
wild-type (F-WT), FLAG-CALR insertion (K385fs*47) mutation (F-INS) or FLAG-CALR deletion (L367fs*46) mutation (F-DEL). Two days later cells
have been sorted for GFP expression and cultured for another 2–5 days before analysis. (i) Real-time PCR for human CALRmRNA levels of Dami
EV, F-WT, F-INS and F-DEL cells is shown. Human CALR mRNA has been normalized to RPLP0 mRNA. Bar graphs depict the fold change in
human CALR mRNA compared with Dami EV. The graph depicts data points generated in triplicates of one representative experiment out of
two. (j) Western blot showing pERK1/2, pMEK1/2 and FLAG protein levels of Dami EV, F-WT, F-INS and F-DEL cells. (k) An anti-FLAG co-
immunoprecipitation was performed with Dami EV, F-WT, F-INS and F-DEL cell extracts and immunoblotted for total CALR. For F-WT only 1/10
of the precipitate volume compared with EV, F-INS and F-DEL has been loaded. (l) 293T cells were transiently transfected with either an EV,
F-WT, F-INS or F-DEL construct. After 24 h FLAG protein levels have been analysed by western blot.
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Figure 4. Mutant CALR is rapidly degraded by the proteosomal machinery. (a) COS-7 cells have been transfected with FLAG-CALR constructs
encoding for GFP on the same vector 24 h prior ﬁxation and microscopy analysis. Cells have been stained with antibodies against BiP, a
protein present in the ER (purple) and FLAG (red). (b) Scheme: 293T cells have been transiently transfected with either FLAG-mCherry-CALR
wild type (mCherry-WT), FLAG-mCherry-CALR insertion (K385fs*47) mutation (mCherry-INS) or FLAG-mCherry-CALR deletion (L367fs*46)
mutation (mCherry-DEL) constructs. At 8–48h after transfection cells have been analysed. (c–e) Mean ﬂuorescence intensity (MFI) of GFP (c), %
mCherry-CALR+ cells of GFP+ gated population (d) and MFI of mCherry-CALR within GFP+ gated population (e) have been analysed in 293T
mCherry-WT, mCherry-INS and mCherry-DEL cells by FACS 8–48h after transient transfection (n= 3). (f) At 24 h after transient transfection 293T
F-WT, F-INS and F-DEL cells were treated with 100 μg/ml cyclohexamide for 1, 2 and 4 h. Western blots show FLAG protein levels for the
different time points (one representative experiment out of two is depicted). (g) At 24 h after transient transfection 293T mCherry-WT,
mCherry-INS and mCherry-DEL cells were treated with 20 μm MG132 and mCherry expression was analysed by FACS over 24 h. GFP
expression was used as a control.
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from CALR-mutant patients were found to harbour increased
levels of pERK1/2 (Figure 5d) with the CD34+ population showing
a similar trend that did not reach signiﬁcance (Supplementary
Figure S5F). Secondly, peripheral blood CD34+ cells from MPN
patients or healthy controls were differentiated in vitro in the
presence of TPO and IL1ß to form CD41+CD42+ megakaryocytes.
Western blotting demonstrated that 4/5 CALR-mutant patients
tested had higher levels of pERK1/2 than all four healthy control
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Figure 5. Mutant CALR inﬂuences megakaryopoiesis and pro-platelet formation. (a) CD34+ cells have been isolated from cord blood and
differentiated into megakaryocytes in the presence of hTPO and hIL-1β. Two days after the isolation cells have been infected with an empty
lentivirus (EV) or a lentivirus encoding for CALR wild type (WT), CALR insertion (K385fs*47) mutation (INS) or CALR deletion (L367fs*46)
mutation (DEL). Cells have been sorted for GFP expression and cultured for another 4 days before FACS analysis or performing a pro-platelet
formation assay. (b) After 8 days of differentiation cells were analysed by FACS for the megakaryocytic surface markers CD41 and CD42. The
graph depicts data points generated by three independent experiments. (c) To perform a platelet formation assay 2 × 103 CD34+ cells
expressing EV, WT, INS or DEL have been seeded on ﬁbrinogen-coated plates after 8 days of differentiation. Data points indicate the number
of pro-platelet-forming cells per 2 × 103 seeded cells 4 days after seeding. Each data point represents one individually infected sample. (d) MFI
pERK1/2 levels of CALR-mutant and JAK2-mutant CD34-cell population compared with normal controls by an intracellular FACS assay. (e)
Peripheral blood-derived CD34+ cells from MPN patients or healthy controls were differentiated in vitro in the presence of TPO and IL1ß to
form CD41+CD42+ megakaryocytes (84.9–96.7% purity at day 10 of differentiation). Shown is a western blot for pERK1/2. (f) Platelets from
CALR-mutant and control peripheral blood have been isolated. The contamination with leukocytes upon puriﬁcation was between 0 and
0.3%. A western blot for pERK1/2 and CALR has been performed and the pERK1/2 to β-actin ratio of CALR patients compared with healthy
controls is depicted in the bottom bar graphs.
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samples (Figure 5e). Thirdly platelets were puriﬁed from CALR-
mutant patients and healthy controls. Western blotting showed
increased levels of pERK1/2 in platelets from all four CALR-mutant
patients compared with healthy controls (Figure 5f).
Together our results demonstrate that MAPK signalling is
increased, not only as a consequence of mutant CALR expression
in vitro but also in primary cells from CALR-mutant patients.
DISCUSSION
Kinases that contribute to cancer represent potential therapeutic
targets. Common screening assays to identify essential kinases
have the disadvantage that the candidate can be hidden within
the off-target noise. In this manuscript we describe an inexpensive
method (KISMET) for identifying essential kinases that takes
advantage of this off-target noise. As proof-of-principle, KISMET
was used to demonstrate that CALR-mutant MARIMO cells are
dependent on MAPK signalling. We go on to show that CALR
mutations result in marked protein instability through proteoso-
mal degradation, but are nonetheless able to activate MAPK
signalling, and enhance megakaryozytic differentiation.
In vitro screens provide a powerful approach to deﬁne
unexpected points of vulnerability in tumour cells. Two common
screening methods used to identify such vulnerabilities are siRNA
and small-molecule library screens. Unintended widespread silencing
of transcripts due to off-target effects can be a problem in siRNA
screens.37 It has been shown that the overlap between indepen-
dently published screens can be very low.38 A recent report
demonstrated that siRNAs screens are even more prone to off-
target effects than already expected.39 In a systematic analysis of
genome-wide siRNA screens in human cells, it was shown that the
observed phenotypes may largely reﬂect ‘seed’-sequence-based off-
target effects. Phenotypes induced by siRNAs correlated with the
seed sequences used and not with the intended gene target.
Making use of kinase inhibitor off-target effects has been
attempted before40 but the lack of a sufﬁciently high number of
inhibitors, comprehensive off-target proﬁles and/or appropriate
algorithms have limited so far the reliability of this approach. By
contrast, we demonstrate here that KISMET predicts the correct
essential kinase with high precision and reliability.
KISMET has several advantages that sets it apart from current
kinase screening options. It is inexpensive, not labour-intensive
(just one dosage per inhibitor sufﬁces for a reliable calculation),
does not require special facilities (for example, for viral work) and
no speciﬁc inhibitors are necessary. The latter is an important
point since, for many kinases, no speciﬁc inhibitor is commercially
available. Furthermore, KISMET can be extended to cover the
entire kinome repertoire and, through the inclusion of additional
inhibitors with known off-target proﬁles, the reliability of the
output increased. Although here we focus on kinase inhibitors, the
KISMET algorithm should also be applicable to additional
compound classes (for example, phosphatase or G-protein
coupled receptor inhibitors) if their off-target proﬁle is known.
We have used KISMET to show that CALR-mutant MARIMO cells
depend on MAPK signalling. Although no changes in RAF and RAS
genes have been found, MARIMO cells may contain other
oncogenic changes and our MARIMO data do not show that
CALR mutations play a causal role in activating the MAPK pathway.
Furthermore, MARIMO cells do not express MPL, suggesting that
that mutant CALR uses an alternative pathway or receptor to
activate the MAPK pathway in MARIMO cells. This hypothesis is
supported by the ﬁnding that mutant CALR can also activate the
JAK–STAT pathway independently of MPL by using the GCSF
receptor.41 However, the MARIMO cell line is so far the only known
human cell line carrying a CALR mutation and could be helpful for
establishing diagnostic tools, one has to be careful when
interpreting molecular data. When we expressed mutant CALR
in murine and human cells we could show a consequent increase
in MEK1/2 and ERK1/2 activation. Moreover, mutant CALR
enhanced megakaryocytic differentiation and pro-platelet forma-
tion which is in line with and extends the recent demonstration
that CALR mutants induce thrombocytosis in vivo.13 These results
are also consistent with previous observations that TPO activates
MAPK pathway in megakaryocytic cell lines,42–45 and that inhibition
of the pathway inhibits megakaryocytic differentiation of CD34+
progenitors puriﬁed from peripheral blood or cord blood.46,47
Interestingly, MEK inhibition not only reduced megakaryocytic
differentiation but also increased erythroid differentiation,46,48
indicating a critical role for the MEK–ERK pathway in regulating the
balance between megakaryopoiesis and erythropoiesis. These
observations are consistent with the fact that, unlike JAK2 mutations,
CALR mutations are found in essential thrombocythaemia and
primary myeloﬁbrosis but not in polycythemia vera.5,6
CALR mutations have also been reported to result in enhanced
tyrosine phosphorylation of STAT5.13 This observation seemed
puzzling given that knocking down STAT5 has been shown to
increase megakaryocytic differentiation.49 However these appar-
ently paradoxical ﬁndings may be reconciled by our recent report
of an unexpected role for tyrosine unphosphorylated STAT5
(uSTAT5) in repressing megakaryocytic differentiation.50 TPO-
induced tyrosine phosphorylation of STAT5 resulted in genome-
wide redistribution of STAT5 and loss of uSTAT5-mediated
repression of a megakaryocytic transcriptional programme. Taken
together our data therefore suggest that the consequences of
CALR mutations for megakarypoiesis are likely to be mediated by
both MAPK and STAT5 pathways.
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